Sustained remission with methotrexate monotherapy after 22-week induction treatment with TNF-alpha inhibitor and methotrexate in early psoriatic arthritis: an open-label extension of a randomized placebo-controlled trial

Sustained remission with methotrexate monotherapy after 22-week induction treatment with TNF-alpha inhibitor and methotrexate in early psoriatic arthritis: an open-label extension of a randomized placebo-controlled trial

Abstract Background If TNF inhibitors are initiated in the early stages of psoriatic arthritis, this could potentially modulate disease and therefore allow us to discontinue the TNF inhibitor after achieving remission. Objective To investigate whether remission induced by tumour necrosis factor alph...

Full description

Bibliographic Details
Main Authors: Henriëtte M. Y. de Jong, Leonieke J. J. van Mens, Michael T. Nurmohamed, Marc R. Kok, Arno W. R. van Kuijk, Dominique L. P. Baeten, Marleen G. H. van de Sande
Format: Article
Language:English
Published: BMC 2019-09-01
Series:Arthritis Research & Therapy
Subjects:
Early psoriatic arthritis
Remission
Treatment withdrawal
Methotrexate
TNF inhibitor
Online Access:http://link.springer.com/article/10.1186/s13075-019-1998-4

Internet

http://link.springer.com/article/10.1186/s13075-019-1998-4

Similar Items